Chardan Capital maintains Buy rating on Adagene, $9 price target

What happened

Chardan Capital kept its Buy rating on Adagene stock and a $9.00 price target. That target implies 248.8% upside from the October 27 close of $2.58, according to the analyst note.

Confirmed

Global impact / market context

A maintained Buy rating and a target far above the last close signal that Chardan sees large potential value in Adagene. For investors, that gap shows how sharply one analyst view can differ from the current stock price.

Analyst inference

Adagene is a drug developer whose value rests on clinical programs like ADG126. Analysts weigh early trial data and its antibody design platform when setting targets, so ratings can move sharply on trial news and financing needs.

Analyst inference

What to watch

1. Watch for new data from ADG126, which is in phase 1b/2 and phase 2 testing for metastatic microsatellite-stable colorectal cancer, since results could shape views on the stock. Confirmed
2. Watch Adagene's spending on its drug programs and any new share sales, because a small developer often needs outside cash to fund trials before revenue arrives. Analyst inference
3. Watch whether other analysts change their ratings or price targets, since a wider gap between analyst targets and the stock price can signal shifting investor views. Analyst inference

Evidence

• Original source link unavailable